The European Commission has authorized TEPKINLY (epcoritamab) combined with lenalidomide and rituximab for treating adults with relapsed or refractory follicular lymphoma (FL). This approval is based on the Phase 3 EPCORE FL-1 trial, which showed the combination significantly improved progression-free survival and response rates compared to standard therapy, with 74% of patients achieving complete remission. TEPKINLY offers a chemotherapy-free alternative, addressing the need for better treatments in this incurable cancer. AbbVie and Genmab continue to explore TEPKINLY's potential in other lymphoma types and earlier treatment stages.

More News (ABBV)

Weight loss drug market to hit $130-150B by 2035, with ETFs like THNR targeting this growth.

The weight loss drug market, driven by GLP-1 therapies, is expected to grow to $130-150 billion by 2035. The Amplify Weight Loss Drug & Treatment ETF (THNR) offers investors targeted exposure to this expanding sector, including major pharmaceutical c...

Market News

Bullish

19 hours ago

Europe approves TEPKINLY combo for relapsed follicular lymphoma, offering a chemo-free treatment option.

More News (ABBV)

Weight loss drug market to hit $130-150B by 2035, with ETFs like THNR targeting this growth.

Invest & Trade with
#1 Award-Winning Investment Super App

Invest

Features

Fees

Learn

Investment Clubs (Coming Soon)

Support

iOS App Store

Google Play Store

Europe approves TEPKINLY combo for relapsed follicular lymphoma, offering a chemo-free treatment option.

More News (ABBV)

Weight loss drug market to hit $130-150B by 2035, with ETFs like THNR targeting this growth.

Invest & Trade with#1 Award-Winning Investment Super App

iOS App Store

Google Play Store

Invest & Trade with
#1 Award-Winning Investment Super App